The FDA named veteran regulator Richard Pazdur director of the Center for Drug Evaluation and Research following George Tidmarsh’s abrupt resignation. Pazdur, a 26‑year agency veteran known for cancer drug stewardship, returns to a senior role that industry and patient groups say will reshape CDER priorities and enforcement. Commentaries and analyses highlight his history of faster approvals balanced by rigorous post‑market actions.